Covid 19
Conditions
Interventions
Test group:HanShiYi decoction
Sponsors
The Affiliated Hospital to Changchun University of Chinese Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients should meet the diagnostic criteria for patients with COVID 19 in China's "New Coronary Virus Pneumonia Diagnosis and Treatment Program (Trial Ninth Version)"; 2. The clinical classification is mild and common type; 3. The first nucleic acid positive time should not exceed 48 hours; 4. The patient's aged >=18 years old; 5. Sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients meet the early warning indicators of severe/critical types; 2. Patients who have used similar proprietary Chinese medicines before enrollment; 3. Immunodeficiency diseases, or those who have used immunosuppressive agents or glucocorticoids within the past 3 months; 4. Women who are planning to become pregnant, pregnant women and lactating women; 5. Patients with allergies (referring to those allergic to more than two kinds of drugs or foods, or to the known ingredients of the drug in this trial); 6. Mental patients, or those without self-awareness; 7. Patients not suitable to participate in clinical trials.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Disappearance time of single symptom;Severe rate;Clinical symptoms recovery time;Nucleic acid test negative time;Hospitalization time;Fever reduction time; | — |
Countries
China
Contacts
Public ContactTong Xiaolin
The Affiliated Hospital to Chagnchun University of Chinese Medicine
Outcome results
None listed